W. Boyle

发表

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice.

D. Lacey, I. Sarosi, J. Delaney, 2000, Proceedings of the National Academy of Sciences of the United States of America.

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

S. Morony, D. Lacey, I. Sarosi, 1998, Genes & development.

Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

J. Penninger, Y. Kong, W. J. Boyle, 2000, Immunology today.

Characterization of osteoclast precursors in human blood

D. Lacey, N. Hawkins, M. Kelley, 2000, British journal of haematology.

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

S. Morony, D. Lacey, D. Goeddel, 1999, Genes & development.

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

D. Lacey, I. Sarosi, J. Delaney, 1998, Cell.

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

G Shimamoto, D. Lacey, T. Boone, 1997, Cell.

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

S. Morony, D. Lacey, M. Bass, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

D L Lacey, D. Lacey, M. Kelley, 2000, The American journal of pathology.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

D L Lacey, P. Kostenuik, S. Morony, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of osteoclastogenesis and RANK expression by TGF‐β1

B. Riggs, B. L. Riggs, S. Khosla, 2001 .